Novozymes A/S Earnings Estimate
Novozymes A/S Earnings per Share Projection vs Actual
About Novozymes A/S Earnings Estimate
The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Novozymes A/S earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Novozymes A/S estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Novozymes A/S fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.Novozymes AS produces and sells industrial enzymes, microorganisms, and probiotics in Europe, the Middle East, Africa, North America, the Asia Pacific, and Latin America. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark. NOVOZYMES is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
Other Information on Investing in Novozymes Pink Sheet
Novozymes A/S financial ratios help investors to determine whether Novozymes Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Novozymes with respect to the benefits of owning Novozymes A/S security.